1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. Arizona >
  6. Exact Sciences Acquires Paradigm Diagnostics

M&A Deal Summary

Exact Sciences Acquires Paradigm Diagnostics

On March 3, 2020, Exact Sciences acquired healthcare services company Paradigm Diagnostics

Acquisition Highlights
  • This is Exact Sciences’ 2nd transaction in the Healthcare Services sector.
  • This is Exact Sciences’ 4th transaction in the United States.
  • This is Exact Sciences’ 2nd transaction in Arizona.

M&A Deal Summary
Date 2020-03-03
Target Paradigm Diagnostics
Sector Healthcare Services
Buyer(s) Exact Sciences
Deal Type Add-on Acquisition

Target

Paradigm Diagnostics

Phoenix, Arizona, United States
Paradigm Diagnostics, Inc. is a medical diagnostics company serving physicians and patients worldwide. The company provides the Paradigm Cancer Diagnostic (PCDx) next-generation sequencing assay to assist physicians and cancer patients to target each patient's specific tumor pathways and genomic changes in their cancer. Through PCDx we assist physicians, patients, and organizations to better understand those fundamental pathways that drive a patient's specific cancer and allow for more effective clinical decision making.

Search 215,074 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Exact Sciences

Madison, Wisconsin, United States
Category Company
Founded 1995
Sector Life Science
Revenue 2.8B USD (2024)
DESCRIPTION

Exact Sciences is a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Exact Sciences was founded in 1995 and is based in Madison, Wisconsin.

DEAL STATS #
Overall 4 of 8
Sector: Healthcare Services M&A 2 of 2
Type: Add-on Acquisition M&A Deals 4 of 7
State: Arizona M&A 2 of 3
Country: United States M&A 4 of 7
Year: 2020 M&A 2 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-03-03 Viomics

Phoenix, Arizona, United States

Viomics, Inc. develops and delivers paradigm-changing cancer detection technologies to enable early and more targeted intervention that cures previously deadly cancers.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-10-27 Thrive Earlier Detection

Cambridge, Massachusetts, United States

Thrive Earlier Detection Corp. is a healthcare company focused on incorporating earlier cancer detection into routine medical care to extend and save lives. Thrive is developing CancerSEEK, a liquid biopsy test that is designed to detect many cancers at earlier stages of the disease. CancerSEEK will serve as the core of Thrive's integrated cancer information offering. Thrive Earlier Detection Corp. was formed in 2019 and is based in Cambridge, Massachusetts.

Buy $2.2B
Mergr

Solution for

Product

Company

Legal